ResMed Inc. (RMD) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

ResMed Inc. (RMD) Healthcare & Pipeline Overview

ResMed Inc. is a global leader in sleep and respiratory care, providing medical devices and cloud-based software solutions. With a focus on innovation and patient outcomes, ResMed serves a wide network of healthcare providers and patients in approximately 140 countries, addressing the growing need for effective respiratory therapies and remote patient monitoring.

What Is the Investment Thesis for RMD?

ResMed Inc. presents a notable research candidate due to its strong market position in the sleep and respiratory care industry, driven by the increasing prevalence of sleep apnea and the growing adoption of remote patient monitoring solutions. The company's consistent profitability, reflected in a profit margin of 27.4%, and a gross margin of 61.7%, highlights its operational efficiency. ResMed's commitment to innovation, particularly in cloud-based software solutions, positions it well to capitalize on the shift towards telehealth and remote healthcare management. The company's dividend yield of 1.13% provides a steady income stream for investors. Key catalysts include ongoing advancements in its software platforms and expansion into new geographic markets. However, potential risks include increased competition and evolving regulatory landscapes in the healthcare sector.

Based on FMP financials and quantitative analysis

RMD Key Highlights

Market capitalization of $31.7B, reflecting its significant presence in the medical device industry.

• P/E ratio of 21.03, indicating a reasonable valuation relative to its earnings.
• Profit margin of 27.4%, showcasing strong profitability and efficient operations.
• Gross margin of 61.7%, demonstrating the company's ability to maintain high pricing power and manage costs effectively.
• Dividend yield of 1.13%, providing a steady income stream for investors.

Who Are RMD's Competitors?

RMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are RMD's Key Strengths?

Strong market position in sleep and respiratory care.

• Innovative cloud-based software solutions.
• Global distribution network.
• High profit and gross margins.

What Are RMD's Weaknesses?

Reliance on a specific niche market (sleep apnea and respiratory disorders).

• Potential for increased competition.
• Exposure to regulatory changes in the healthcare industry.

What Could Drive RMD Stock Higher?

Continued adoption of remote patient monitoring solutions driven by telehealth trends.

• Launch of new and improved CPAP and BiPAP devices with enhanced features.
• Expansion of cloud-based software solutions to new healthcare providers and patients.
• Potential strategic acquisitions to expand product portfolio and market reach.

What Are the Key Risks for RMD?

Insider selling — insiders were net sellers of roughly $6.2M recently.

• Increased competition from existing and new players in the sleep and respiratory care market.
• Evolving regulatory landscape in the healthcare sector, which could impact product approvals and reimbursement rates.
• Economic downturns affecting healthcare spending and patient access to medical devices.
• Patent expirations and generic competition, which could erode market share and pricing power.

What Are the Growth Opportunities for RMD?

• Expansion of Cloud-Based Solutions: ResMed has a significant opportunity to expand its cloud-based software solutions, such as AirView and myAir, to a broader range of healthcare providers and patients. The market for remote patient monitoring is projected to reach $30 billion by 2028, driven by the increasing adoption of telehealth and the need for efficient healthcare management. By enhancing its software capabilities and integrating them with its medical devices, ResMed can improve patient outcomes and increase recurring revenue streams.
• Geographic Expansion: ResMed can further expand its presence in emerging markets, where the prevalence of sleep apnea and other respiratory disorders is growing. These markets offer significant growth potential due to increasing healthcare awareness and improving access to medical services. By establishing strategic partnerships and tailoring its products to local needs, ResMed can capture a larger share of the global respiratory care market.
• Product Innovation: Continuous innovation in medical device technology and software solutions is crucial for ResMed's growth. The company can invest in developing more advanced CPAP and BiPAP devices, as well as exploring new therapies for respiratory disorders. By staying at the forefront of technological advancements, ResMed can maintain its competitive edge and attract new customers.
• Strategic Acquisitions: ResMed can pursue strategic acquisitions to expand its product portfolio and enter new market segments. Acquiring companies with complementary technologies or distribution networks can accelerate its growth and strengthen its market position. For example, acquiring a company specializing in home healthcare services could enhance ResMed's ability to provide comprehensive respiratory care solutions.
• Partnerships with Healthcare Providers: Collaborating with hospitals, sleep clinics, and home healthcare providers can create new opportunities for ResMed. By offering integrated solutions that improve patient outcomes and reduce healthcare costs, ResMed can become a preferred partner for healthcare providers. These partnerships can also provide valuable insights into patient needs and market trends, enabling ResMed to develop more effective products and services.

What Are RMD's Competitive Advantages?

• Strong brand reputation and established market leadership in the sleep and respiratory care industry.
• Extensive patent portfolio protecting its medical device technology and software solutions.
• Integrated cloud-based software solutions that enhance patient outcomes and provide recurring revenue streams.
• Global distribution network and established relationships with healthcare providers.

What Does RMD Do?

Founded in 1989 and headquartered in San Diego, California, ResMed Inc. has evolved into a global leader in the development, manufacturing, and distribution of medical devices and cloud-based software solutions for the healthcare market. The company's primary focus is on addressing respiratory disorders, with a strong emphasis on sleep apnea and other related conditions. ResMed operates through two main segments: Sleep and Respiratory Care, and Software as a Service (SaaS). Its product portfolio includes a wide array of medical devices, such as continuous positive airway pressure (CPAP) machines, bilevel positive airway pressure (BiPAP) devices, ventilation devices, diagnostic products, and various mask systems for both hospital and home use. These products are complemented by a range of accessories, including headgear and dental devices. ResMed's cloud-based software solutions, such as AirView, myAir, and U-Sleep, enable remote patient monitoring, personalized therapy management, and streamlined sleep program management for home medical equipment (HME) providers. Additionally, ResMed offers out-of-hospital software solutions like Brightree, MatrixCare, and HEALTHCAREfirst, catering to various healthcare providers, including HME suppliers, pharmacies, senior living facilities, and home health agencies. The company markets its products and services through a network of distributors and a direct sales force, reaching sleep clinics, home healthcare dealers, and hospitals in approximately 140 countries.

What Products and Services Does RMD Offer?

• Develops and manufactures medical devices for sleep apnea and respiratory disorders.
• Offers cloud-based software solutions for remote patient monitoring and therapy management.
• Provides CPAP and BiPAP machines, ventilation devices, and diagnostic products.
• Distributes mask systems and accessories for hospital and home use.
• Offers out-of-hospital software solutions for home medical equipment (HME) providers.
• Provides electronic health record, billing, and analytics services for home health and hospice agencies.
• Markets products through distributors and a direct sales force in approximately 140 countries.

How Does RMD Make Money?

• Sales of medical devices, including CPAP and BiPAP machines, ventilation devices, and diagnostic products.
• Subscription revenue from cloud-based software solutions, such as AirView and myAir.
• Service revenue from out-of-hospital software solutions, including Brightree and MatrixCare.
• Recurring revenue from accessories, such as masks and headgear.

What Industry Does RMD Operate In?

ResMed Inc. operates in the medical instruments and supplies industry, which is experiencing growth driven by an aging population, increasing prevalence of chronic respiratory diseases, and technological advancements in remote patient monitoring. The market is competitive, with key players like Becton, Dickinson and Company (BDX), Cardinal Health, Inc. (CAH), and Alcon Inc. (ALC). ResMed distinguishes itself through its focus on sleep and respiratory care, coupled with its integrated cloud-based software solutions, positioning it favorably in the evolving healthcare landscape.

Who Are RMD's Key Customers?

• Sleep clinics and hospitals.
• Home healthcare dealers.
• Patients with sleep apnea and other respiratory disorders.
• Home medical equipment (HME) providers.
• Senior living facilities and skilled nursing facilities.

Over the past six months, ResMed Inc. insiders filed 14 SEC Form 4 transactions — 10 sales and 4 purchases. On net that is roughly 29K shares disposed (about $6.2M), a signal worth weighing alongside the fundamentals.

Quarterly Financial Performance: ResMed Inc.

Revenue for ResMed Inc. came in at $1.46B during Q4 FY2026, a 2.3% improvement versus the preceding quarter. The company recorded net income of $383.4M, with diluted EPS of $2.64. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this large-cap Healthcare company. Across the four most recent quarters, RMD averaged $2.60 in diluted EPS.

RMD Valuation & Market Position

With a $31.7B market cap, ResMed Inc. sits in the large-cap segment of the market. Analyst price targets span from $213.00 to $300.00, with a consensus of $239.90. At the current price of $218.27, that implies approximately 10% upside potential. Relative to its peer group, RMD's quantitative score of 93/100 is above the peer average of 75/100.

Return on equity for ResMed Inc. stands at 23.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 17.0%, showing how much profit it generates from its asset base. RMD trades at a trailing price-to-earnings ratio of 21.03, roughly in line with the Healthcare sector average of ~21.50x. Its free cash flow yield is 8.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.10 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.7%, the inverse of the P/E and a quick read on earnings relative to price.

ResMed Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 10.91 places it in the safe zone, indicating low near-term bankruptcy risk.

ResMed Inc. has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 3.0% above estimates on average.

Company Profile

ResMed Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Michael J. Farrell. RMD has traded publicly since 1995.

RMD Financials

Next earnings report: Oct 29, 2026

RMD Latest News

RMD Analyst Consensus

RMD MoonshotScore

What Investors Ask About ResMed Inc. (RMD) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources